Accessed - 14 times.

B.V.S. Lakshmi1*, Ram Babu2, M. Sudhakar1, E. Yashita3, B. Varshita3, V. Swapna3, K. Vennela3.
1Department of Pharmacology, Malla Reddy College of Pharmacy (Affiliated to Osmania University), Dhulapally , Secunderabad- 500014, Telangana, INDIA.
2Department of General Medicine, Malla Reddy Institute of Medical Sciences, Suraram, Hyderabad, Telangana, INDIA.
3Department of Pharmacy Practice, Malla Reddy College of Pharmacy (Affiliated to Osmania University), Dhulapally, Secunderabad- 500014, Telangana, INDIA.

Volume 6, Issue 1, Page 1-7.

*Author for correspondence

Background: Cardiovascular diseases (CVD) are the major cause of morbidity and mortality in our society with Dyslipidemia contributing significantly to atherosclerosis. Thus measurement of plasma lipids would help in identifying people at risk for CVD.
Materials and methods: The study included 158 consecutive Dyslipidemic patients above 25 years of age. Patient selection was done by simple random sampling into three equal groups (A, B, C) who were newly prescribed with Atorvastatin 10mg, 20mg, 40mg respectively and their sociodemographic, height, weight, and physical activities were collected from patient’s Medical Records. In week 9 each group is divided into further two subgroups i.e. control group (drug therapy + subjects regular diet) and experimental group (drug therapy + DASH diet) and recorded the data of those subjects and the efficacy was determined and compared.
Results: In the present study, the % mean change of all three doses (10mg, 20mg and 40mg) reduced the lipid levels (TC, LDL, TG, VLDL) from baseline to week 8. A dose-dependent response was apparent with greater decreases achieved by patients receiving the higher doses (20 and 40 mg) of Atorvastatin when compared to the lower dose (10mg). The present study also showed that the patient groups who followed the DASH diet along with Atorvastatin (experimental group) had the significant reduction in lipid levels when compared to that of patient groups who followed their regular diet with Atorvastatin (control group).
Conclusion: In the present study, the results showed that the effects of Atorvastatin on lipid profile was similar-considering 40mg and 20mg dosages of the drug and thus administration of the lower dose of the drug (20mg) might be more preferable. In the second phase of the present study, Atorvastatin Experimental group (following DASH diet + drug) was found to be most effective at reducing lipid levels when compared to control group (following subjects regular diet + drug).
Keywords: Atorvastatin, Dyslipidemic patients, Incidence of adverse effects, DASH diet, Lipid levels, Simple randomization.